The global P2X7 receptor antagonists market, by Drugs (AKP-23494954/RQ-00466479, EVT 401, GSK1482160, JNJ-55308942, JNJ-54175446, and Others (e.g.- AZ11657312)), by Application (Central Nervous System Disorders, Immunological Disorders, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is expected to be valued at US$ 135.2 million in 2026, and is projected to exhibit a CAGR of 18.3% over the forecast period.
P2X7 receptor antagonists of Johnson & Johnson are considered while estimating the size of the global P2X7 receptor antagonist market over the period 2024 to 2026. Currently only two companies’ molecules are in phase 1 trials in the U.S. i.e. Johnson & Johnson, and GlaxoSmithKline. JNJ-55308942 (Johnson & Johnson) is in Phase 1 clinical trials and is indicated for the treatment of mood disorders. Study start date for JNJ-55308942 was March 15, 2018, and ended on October 19, 2018. Another drug, JNJ-54175446 (Johnson & Johnson, study started on March 24, 2017, and ended on November 14, 2017) is also in Phase 1 clinical trials indicated for the treatment of a major depressive disorder. It is assumed that Johnson & Johnson will complete clinical trials in 2023 and will be able to launch the products in the market in the year 2024, as various phase 1 studies have been conducted for Johnson & Johnson drugs which would boost global P2X7 receptor antagonist market growth. These factors are expected to support global P2X7 receptor antagonist market growth over the forecast period.
Browse 16 Market Data Tables and 14 Figures spread through 94 Pages and in-depth TOC on Global P2X7 Receptor Antagonists Market, by Drugs (AKP-23494954/RQ-00466479, EVT 401, GSK1482160, JNJ-55308942, JNJ-54175446, and Others (e.g.- AZ11657312)), by Application (Central Nervous System Disorders, Immunological Disorders, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026
To know the latest trends and insights prevalent in the Global P2X7 Receptor Antagonists Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/p2x7-receptor-antagonists-market-2595
In March 2018, Asahi Kasei Pharma Corporation and RaQualia Pharma Inc. entered into a license agreement for a novel P2X7 receptor antagonist. Under this agreement, Asahi Kasei Pharma obtained exclusive rights for worldwide development, manufacture, and sale of P2X7 receptor antagonist, while RaQualia Pharma will receive a lump-sum payment as well as milestone payments corresponding to stages of development, and royalty payments in proportion to sales amounts. The P2X7 antagonist is AKP-23494954/RQ-00466479. In 2016, CONBA Pharmaceutical revised the synthetic route for EVT401. Furthermore, additional pre-clinical pharmacokinetics and safety studies are being conducted in order to meet the requirements of the China Food and Drug Administration prior to seeking approval for further clinical studies. In 2012, Evotec AG granted exclusive rights for EVT401 in China to CONBA Pharmaceutical. These factors are expected to support global P2X7 receptor antagonist market growth over the forecast period.
Key Takeaways of the Global P2X7 Receptor Antagonists Market:
- The global P2X7 receptor antagonists market is expected to exhibit a CAGR of 18.3% over the forecast period. This is owing to launch of P2X7 receptor antagonists late in the forecast period
- Manufacturers are working towards development of P2X7 receptor antagonists and expect to launch these over the forecast period supporting global P2X7 receptor market growth over the forecast period
- North America is expected to hold a dominant position in the global P2X7 receptor antagonists market over the forecast period, owing to product launches and potential customer base
- Major players operating in the global P2X7 receptor antagonists market include, GlaxoSmithKline Plc, Johnson & Johnson, AstraZeneca Plc, RaQualia Pharma, Evotec AG, and Asahi Kasei Corporation
